Haematological care of the jehovah's witness patient*
2002; Wiley; Volume: 119; Issue: 1 Linguagem: Inglês
10.1046/j.1365-2141.2002.03639.x
ISSN1365-2141
Autores Tópico(s)Trauma, Hemostasis, Coagulopathy, Resuscitation
ResumoBritish Journal of HaematologyVolume 119, Issue 1 p. 25-37 Haematological care of the jehovah's witness patient* Judith C. W. Marsh, Judith C. W. Marsh Department of Haematology, St George's Hospital NHS Trust, London, UKSearch for more papers by this authorDavid H. Bevan, David H. Bevan Department of Haematology, St George's Hospital NHS Trust, London, UKSearch for more papers by this author Judith C. W. Marsh, Judith C. W. Marsh Department of Haematology, St George's Hospital NHS Trust, London, UKSearch for more papers by this authorDavid H. Bevan, David H. Bevan Department of Haematology, St George's Hospital NHS Trust, London, UKSearch for more papers by this author First published: 02 October 2002 https://doi.org/10.1046/j.1365-2141.2002.03639.xCitations: 49 David H. Bevan, Department of Haematology, St George's Hospital NHS Trust, London SW17 0RE, UK. E-mail: [email protected] * This annotation is dedicated to the memory of D.H. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat References Archimbaud, E., Ottmann, O., Liu Yin, J.A., Lechner, K., Dombret, H., Sanz, M.A., Herrmann, F., Gruss, H., Fenaux, P., Ganser, A., Heil, G., Kanz, L., Brugger, W., Sims, T., Olsen, K. & Hoelzer, D. (1996) A randomised double-blind, placebo-controlled study using PEG-rHuMGDF as an adjunct to chemotherapy for adults with de novo acute myeloid leukaemia: early results. Blood, 88, 447a. Web of Science®Google Scholar Association of Anaesthetists of Great Britain and Ireland (1999) Management of Anaesthesia for Jehovahs' Witnesses. Google Scholar Ballen, K.K., Ford, P.A., Waitkus, H., Emmons, R.V., Levy, W., Doyle, P., Stewart, F.M., Quesenberry, P.J. & Becker, P.S. (2000) Successful autologous bone marrow transplant without the use of blood product support. Bone Marrow Transplantation, 26, 227–229. 10.1038/sj.bmt.1702483 CASPubMedWeb of Science®Google Scholar Basser, R.L., Rasko, J., Clarke, K., Cebon, J., Green, M.D., Grigg, A., Zalcberg, J., Cohen, B., O'Bryne, J., Menchaca, D.M., Fox, R.M. & Begley, C.G. (1997) Randomised, blinded, placebo-controlled phase I trial of pegylated recombinant human megakaryocyte growth and development factor with filgrastim after dose-intensive chemotherapy in patients with advanced cancer. Blood, 89, 3118–3128. CASPubMedWeb of Science®Google Scholar Bell, K., Stott, K., Sinclair, C.J. & Gillon, J. (1992) A controlled trial of intraoperative autologous transfusion in cardiothoracic surgery measuring effect on transfusion requirements and clinical outcome. Transfusion Medicine, 2, 295–300. 10.1111/j.1365-3148.1992.tb00173.x CASPubMedWeb of Science®Google Scholar Blutters-Sawatzki, R. & Bertram, U. (1992) Introduction of erythropoietin in the treatment of acute lymphoblastic leukemia (ALL) in a patient of Jehovah's Witnesses Persuasion: a case report. Medical and Pediatric Oncology, 2, 23–25. 10.1002/mpo.2950200706 CASPubMedGoogle Scholar Boggs, D.R. (1985) Jehovah's Witnesses with leukemia. Hospital Practice, 20, 92–98. 10.1080/21548331.1985.11703015 CASPubMedWeb of Science®Google Scholar British Committee for Standards in Haematology, Blood Transfusion Task Force (2001) Guidelines for the clinical use of red cell transfusions. British Journal of Haematology, 113, 24–31. 10.1046/j.1365-2141.2001.02701.x CASPubMedWeb of Science®Google Scholar Broccia, G. (1994) Long term continuous complete remission of acute myeloid leukemia in a Jehovah's Witness treated without blood support. Haematologica, 79, 180–181. CASPubMedWeb of Science®Google Scholar Camitta, B.M., Thomas, E.D., Nathan, D.G., Santos, G., Gordon-Smith, E.C., Gale, R.P., Rappeport, J.M. & Storb, R. (1976) Severe aplastic anemia: a prospective study on the effect of early marrow transplantation on acute mortality. Blood, 48, 63–70. CASPubMedWeb of Science®Google Scholar Carson, J.L., Duff, A., Berlin, J.A., Lawrence, V.A., Poses, R.M., Huber, E.C., O'Hara, D.A., Noveck, H. & Strom, B.L. (1998) Perioperative blood transfusion and post operative mortality. Journal of the American Association of Medicine, 279, 199–205. 10.1001/jama.279.3.199 CASPubMedWeb of Science®Google Scholar Cazzola, M., Mercuriali, F. & Brugnan, C. (1997) Use of recombinant human erythropoietin outside the setting of uremia. Blood, 89, 4248–4267. 10.1182/blood.V89.12.4248 CASPubMedWeb of Science®Google Scholar Clagett, G.P., Valentine, R.J. & Jackson, M.R. (1999) A randomised trial of intraoperative transfusion during aortic surgery. Journal of Vascular Surgery, 29, 22–30. 10.1016/S0741-5214(99)70346-0 CASPubMedWeb of Science®Google Scholar Clay, M.A. (1999) Ethical and legal implications of bloodless medicine and surgery. Journal of Intensive Care Medicine, 14, 34–40. 10.1046/j.1525-1489.1999.00034.x Web of Science®Google Scholar Corash, L. (2000) New technologies for the inactivation of infectious pathogens in cellular blood components and the development of platelet substitutes. Bailliere's Clinical Haematology, 13, 549–563. 10.1053/beha.2000.0099 CASPubMedWeb of Science®Google Scholar Couban, S. & Wilson, W.E.C. (1995) Use of 2-chlorodeoxyadenosine, granulocyte-colony stimulating factor, and erythropoietin in a Jehovah's Witness with hairy cell leukaemia. American Journal of Hematology, 49, 255–256. 10.1002/ajh.2830490318 CASPubMedWeb of Science®Google Scholar Cullis, J.O. & Smith, A.G. (1990) Jehovah's Witnesses with leukaemia. Lancet, 336, 1075–1076. 10.1016/0140-6736(90)92554-U CASPubMedWeb of Science®Google Scholar Cullis, J.O., Duncombe, A.S., Dudley, J.M., Lumley, H.S., Apperley, J.F. & Smith, A.G. (1998) Acute leukemia in Jehovah's Witnesses. British Journal of Haematology, 100, 664–668. 10.1046/j.1365-2141.1998.00634.x CASPubMedWeb of Science®Google Scholar D'Oiron, R., Menart, C., Trzeciak, M.C., Nurden, P., Fressinaud, E., Dreyfus, M., Laurian, Y. & Negrier, C. (2000) Use of recombinant factor VIIa in 3 patients with inherited type I Glanzmann's thrombasthenia undergoing invasive procedures. Thrombosis and Haemaostasis, 83, 644–647. CASPubMedWeb of Science®Google Scholar Dainer, P.M., Knupp, C.L. & Sartiano, G.P. (1992) Low dose cytosine arabinoside as an alternative treatment for acute leukemia in Jehovah's Witnesses. American Journal of Hematology, 40, 156–157. 10.1002/ajh.2830400219 CASPubMedWeb of Science®Google Scholar Desmond, M.J., Thomas, M.J., Gillon, J. & Fox, M.A. (1996) Consensus conference on autologous transfusion. Perioperative red cell salvage. Transfusion, 36, 644–651. 10.1046/j.1537-2995.1996.36796323065.x PubMedWeb of Science®Google Scholar Desmond, M., Gillon, J. & Thomas, M.J.G. (1999) Perioperative red cell salvage: a case for implementing the consensus statement. Transfusion Medicine, 9, 265–268. 10.1046/j.1365-3148.1999.00206.x CASPubMedWeb of Science®Google Scholar Elder, L. (2000) Why some Jehovah's Witnesses accept blood and conscientiously reject official Watchtower Society blood policy. Journal of Medical Ethics, 26, 375–380. 10.1136/jme.26.5.375 CASPubMedWeb of Science®Google Scholar Estrin, J.T., Ford, P.A., Henry, D.H., Stradden, A.P. & Mason, B.A. (1997) Erythropoietin permits high-dose chemotherapy with peripheral blood stem-cell transplant for a Jehovah's Witness. American Journal of Hematology, 55, 51–52. 10.1002/(SICI)1096-8652(199705)55:1 3.0.CO;2-9 CASPubMedWeb of Science®Google Scholar Fanucchi, M., Glaspy, J., Crawford, J., Garst, J., Figlin, R., Sheridan, W., Menchaca, D., Tomita, D., Ozer, H. & Harker, L. (1997) Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer. New England Journal of Medicine, 336, 404–409. 10.1056/NEJM199702063360603 CASPubMedWeb of Science®Google Scholar Frickhofen, N. & Rosenfeld, S.J. (2000) Immunosuppressive therapy of aplastic anaemia with antithymocyte globulin and cyclosporine. Seminars in Hematology, 37, 56–68. 10.1016/S0037-1963(00)90030-1 CASPubMedWeb of Science®Google Scholar Gillon, R. (2000) Refusal of potentially life-saving blood transfusions by Jehovah's Witnesses: should doctors explain that not all JWs think it's religiously required? Journal of Medical Ethics, 26, 299–301. 10.1136/jme.26.5.299 CASPubMedWeb of Science®Google Scholar Goldberg, S.L., Chan, C.S.P., Dawkins, F.W., Mehlman, M.D. & Schechter, G.P. (1990) Should Jehovah's Witnesses be denied intensive chemotherapy for acute leukemia? New England Journal of Medicine, 322, 777. 10.1056/NEJM199003153221115 CASPubMedWeb of Science®Google Scholar Goodnough, L.T., Monk, T.G. & Brecher, M.E. (1998) Acute normovolaemic hemodilution should replace the preoperative donation of autologous blood as a method of autologous-blood procurement. Transfusion, 38, 473–476. 10.1046/j.1537-2995.1998.38598297217.x CASPubMedWeb of Science®Google Scholar Goodnough, L.T., Brecher, M.E., Kanter, M.H. & AuBuchon, J.P. (1999a) Transfusion medicine, first of two parts: blood transfusion. New England Journal of Medicine, 340, 438–447. 10.1056/NEJM199902113400606 CASPubMedWeb of Science®Google Scholar Goodnough, L.T., Brecher, M.E., Kante, M.H. & AuBuchon, J.P. (1999b) Transfusion medicine, second of two parts: blood conservation. New England Journal of Medicine, 340, 525–533. 10.1056/NEJM199902183400706 CASPubMedWeb of Science®Google Scholar Hargis. J.B., Waddell, D.J., Diehl, L. & Redmond, J. (1990) Induction chemotherapy in Jehovah's Witnesses with leukaemia. Lancet, 336, 563–564. 10.1016/0140-6736(90)92117-Z CASPubMedWeb of Science®Google Scholar Hedner, U. (1999) Treatment of patients with factor VIII and factor IX inhibitors with special focus on the use of recombinant factor VIIa. Thrombosis and Haemostasis, 82, 531–534. CASPubMedWeb of Science®Google Scholar Heimpel, H. (1993) Therapy of aplastic anaemia: is a consensus possible?. In: Aplastic Anaemia: Current Perspectives on the Pathogenesis and Treatment (ed. by H. Schrezenmeier & N. Frickhofen), pp. 154–159. Blackwell-MZV, Holland. Google Scholar Herbert, P.C., Wells, G., Morris, A., Blajchman, M.A., Marshall, J., Martin, C., Pagliavello, G., Tweeddale, M., Schweitzer, I., Yetisir, E. & the Transfusion Requirements in Critical Care Iinvestigators for the Canadian Critical Care Trials Group (1999) A multicenter, randomised, controlled clinical trial of transfusion requirements in critical care. New England Journal of Medicine, 340, 409–417. 10.1056/NEJM199902113400601 CASPubMedWeb of Science®Google Scholar Hoffman, M., Monroe, III, D.M. & Roberts, H.R. (1998) Activated factor VIIa activates factors IX and X on the surface of activated platelets: thoughts on the mechanism of action of high-dose activated factor VII. Blood Coagulation and Fibrinolysis, 9, S61–S65. CASPubMedWeb of Science®Google Scholar Kaito, K., Kobayashi, M., Sakamoto, M., Shimada, T., Masuoka, H., Nishiwaki, K., Saeki, A., Sekita, T., Otsubo, H. & Hosoya, T. (1998) Combination chemotherapy with G-CSF, M-CSF and Epo: successful treatment for acute myelogenous leukemia without blood transfusion at lower medical costs. Acta Haematologica, 100, 57–60. 10.1159/000040865 CASPubMedWeb of Science®Google Scholar Kaushansky, K. (2000) Use of thrombopoietic growth factors in acute leukaemia. Leukaemia, 14, 505–508. 10.1038/sj.leu.2401620 CASPubMedWeb of Science®Google Scholar Kerridge, I., Lowe, M., Seldon, M., Enno, A. & Deveridge, S. (1997) Clinical and ethical issues in the treatment of a Jehovah's Witness with acute myeloblastic leukemia. Archives of Internal Medicine, 157, 1753–1757. 10.1001/archinte.157.15.1753 CASPubMedWeb of Science®Google Scholar Klein, H.G. (2000) The prospects for red-cell substitutes. New England Journal of Medicine, 342, 1666–1668. 10.1056/NEJM200006013422211 CASPubMedWeb of Science®Google Scholar Lin, C.-P., Huang, M.-J., Liu, H.-J. & Tsai, C.-H. (1996) Successful treatment of acute promyelocytic leukemia in a pregnant Jehovah's Witness with all-trans retinoic acid, rhG-CSF, and erythropoietin. American Journal of Hematology, 51, 251–252. 10.1002/(SICI)1096-8652(199603)51:3 3.0.CO;2-I CASPubMedWeb of Science®Google Scholar Malyon, D. (1998) Transfusion-free treatment of Jehovah's Witnesses: respecting the autonomous patient's rights. Journal of Medical Ethics, 24, 302–307. 10.1136/jme.24.5.302 CASPubMedWeb of Science®Google Scholar Marsh, J.C.W. (2000) Hematopoietic growth factors in the pathogenesis and for the treatment of aplastic anemia. Seminars in Hematology, 37, 81–90. 10.1016/S0037-1963(00)90032-5 CASPubMedWeb of Science®Google Scholar Mason, J.K. & McCall Smith, R.A. (1994) Law and Medical Ethics, 4th edn, pp. 229–231. Butterworths, London. Google Scholar Mazza, P., Palazzo, G., Amurri, B., Cervellera, M., Rizzo, C. & Maggi, A. (2000) Acute leukemia in Jehovah's Witnesses: a challenge for hematologists. Haematologica, 85, 1221–1222. CASPubMedWeb of Science®Google Scholar Menedez, A., Svarch, E., Martinez, G. & Hernandez, P. (1998) Successful treatment of acute promyelocytic leukemia using all-trans retinoic acid and erythropoietin in a Jehovah's Witness boy. Annals of Hematology, 76, 43–44. 10.1007/s002770050359 PubMedWeb of Science®Google Scholar Muramoto, O. (2000) Medical confidentiality and the protection of Jehovah's Witnesses' autonomous refusal of blood. Journal of Medical Ethics, 26, 381–386. 10.1136/jme.26.5.381 CASPubMedWeb of Science®Google Scholar Muramoto, O. (2001) Bioethical aspects of the recent changes in the policy of refusal of blood by Jehovah's Witnesses. British Medical Journal, 322, 37–39. 10.1136/bmj.322.7277.37 CASPubMedWeb of Science®Google Scholar NHS Executive (1998) Health Service Circular. Better Blood Transfusion HSC224. NHS, London. Google Scholar Nousiainen, T., Jantunen, E. & Lahtinen, R. (1993) Jehovahs' Witnesses with acute leukemia. American Journal of Hematology, 43, 158–159. 10.1002/ajh.2830430225 CASPubMedWeb of Science®Google Scholar Pegelow, C.H., Adams, R.J., McKie, V., Abboud, M., Berman, B., Miller, S.T., Olivieri, N., Vichinsky, E., Wang, W. & Brambilla, D. (1995) Risk of recurrent stroke in patients with sickle cell disease treated with erythrocyte transfusions. Journal of Pediatrics, 126, 896–899. 10.1016/S0022-3476(95)70204-0 CASPubMedWeb of Science®Google Scholar Re, S. (1992) (A Minor) (Medical Treatment) 4 All ER 671. Google Scholar Re, T. (1992) (Adult) (Refusal of Medical Treatment) 4 All ER 649, 9 BMLR 46, CA. Google Scholar Ridley, D. (1999) Jehovah's Witnesses refusal of blood: obedience to scripture and religious conscience. Journal of Medical Ethics, 25, 469–472. 10.1136/jme.25.6.469 CASPubMedWeb of Science®Google Scholar Rohling, R.G., Zimmerman, A.P. & Breymann, C. (2000) Intravenous versus oral iron supplementation for preoperative stimulation of hemoglobin synthesis using recombinant human erythropoietin. Journal of Hematotherapy and Stem Cell Research, 9, 497–500. 10.1089/152581600419161 CASPubMedWeb of Science®Google Scholar Royal College of Physicians of Edinburgh (1996) Consensus conference on autologous transfusion: final consensus statement. Transfusion, 36, 667. Google Scholar Royal College of Physicians of Edinburgh (1999) Autologous transfusion, 3 years on: What is new? What has happened? Transfusion, 39, 910–911. 10.1046/j.1537-2995.1999.39080910.x PubMedWeb of Science®Google Scholar Royal College of Surgeons of England (1996) Code of Practice for the Surgical Management of Jehovah's Witnesses. Google Scholar Samuelsson, G. (2001) Extracorporeal immunoadsorption with protein A: technical aspects and clinical results. Journal of Clinical Apheresis, 16, 49–52. 10.1002/jca.1012 CASPubMedWeb of Science®Google Scholar Sievers, E.L., Larson, R.A., Stadtmauer, E.A., Estey, E., Lowenberg, B., Dombret, H., Karanes, C., Theobald, M., Bennett, J.M., Sherman, M.L., Berger, M.S., Eten, C.B., Loken, M.R., Van Dongen, J.J., Bernstein, I.D. & Appelbaum, F.R. (2001) Efficacy and safety of gemtuzumab ozogamicin in patients with CD-33-positive acute myeloid leukaemia in first relapse. Journal of Clinical Oncology, 19, 3244–3254. 10.1200/JCO.2001.19.13.3244 CASPubMedWeb of Science®Google Scholar Smith, S. (2001) The role of the court in ethical decision making. Clinical Medicine (JRCPL), 1, 371–373. 10.7861/clinmedicine.1-5-371 CASWeb of Science®Google Scholar Takeuchi, S., Utsunomiya, A., Makino, T., Shimotakahara, S., Takatsuka, Y., Kawabata, H. & Nakashima, A. (1999) Successful treatment for acute lymphoblastic leukemia without blood transfusion in a Jehovah's Witness. American Journal of Hematology, 60, 167–172. 10.1002/(SICI)1096-8652(199902)60:2 3.0.CO;2-S Web of Science®Google Scholar Thomas, M.J.G. (1999) Infected and malignant fields are an absolute contraindication to intraoperative cell salvage: fact or fiction? Transfusion Medicine, 9, 269–278. 10.1046/j.1365-3148.1999.00207.x CASPubMedWeb of Science®Google Scholar Viele, M.K. & Weiskopf, R.B. (1993) What can we learn about the need for transfusion from patients who refuse blood? The experience with Jehovah's Witnesses. Transfusion, 34, 396–401. 10.1046/j.1537-2995.1994.34594249050.x Web of Science®Google Scholar Watchtower Bible and Tract Society (1981) Disfellowship – how to view it. Watchtower, September 15, 20–26. Google Scholar Watchtower Bible and Tract Society (2000) Questions from readers. Watchtower, June 15, 29–31. Google Scholar Williamson, L.M., Lowe, S., Love, E.M., Cohen, H., Soldan, K., McClelland, D.B.L., Skacel, P. & Barbera, J.A.J. (1999) Serious hazards of transfusion (SHOT) initiative: analysis of the first two annual reports. British Medical Journal, 319, 16–19. 10.1136/bmj.319.7201.16 CASPubMedWeb of Science®Google Scholar Williamson, K.R. & Taswell, H.F. (1991) Intraoperative blood salvage: a review. Transfusion, 31, 662–675. 10.1046/j.1537-2995.1991.31791368347.x CASPubMedWeb of Science®Google Scholar Yate, R.M., Milling, M.A.P. & McFadzean, W. (2000) Treatment without consent: a medicolegal precedent. Lancet, 356, 69. 10.1016/S0140-6736(00)02444-2 CASPubMedWeb of Science®Google Scholar Citing Literature Volume119, Issue1October 2002Pages 25-37 ReferencesRelatedInformation
Referência(s)